Scarica l'app Stockscreener
25.69
3.55%
0.88
Dopo l'orario di chiusura:
25.69
Lb Pharmaceuticals Inc Borsa (LBRX) Ultime notizie
Biotech developing schizophrenia therapies lines up March investor pitch - Stock Titan
LB Pharmaceuticals Presents New Data on LB-102's Potential to Improve Cognitive Performance in Schizophrenia - National Today
LB Pharmaceuticals presents LB-102 cognitive data at SIRS meeting By Investing.com - Investing.com Australia
LB Pharmaceuticals presents LB-102 cognitive data at SIRS meeting - Investing.com
LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102’s Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS) - ChartMill
LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Releases Quarterly Earnings Results, Meets Estimates - marketbeat.com
Stifel raises LB Pharmaceuticals stock price target to $40 By Investing.com - Investing.com India
JPMorgan Chase & Co. Buys Shares of 1,032,603 LB Pharmaceuticals Inc $LBRX - MarketBeat
LBRX: LB-102 shows strong efficacy and safety in late-stage trials, targeting major neuropsychiatric markets - TradingView
LB Pharmaceuticals (NASDAQ: LBRX) advances LB-102 in schizophrenia and bipolar depression - Stock Titan
LB Pharmaceuticals Inc Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
LB Pharmaceuticals Inc.: Q4 Earnings Snapshot - Barchart.com
[8-K] LB PHARMACEUTICALS INC Reports Material Event - Stock Titan
LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Yahoo Finance
LB Pharmaceuticals commences Phase III schizophrenia trial - Yahoo
LB Pharmaceuticals starts phase 3 trial for schizophrenia drug By Investing.com - Investing.com India
LB Pharmaceuticals starts phase 3 trial for schizophrenia drug - Investing.com
LB Pharmaceuticals initiates pivotal phase 3 trial (Nova-2) for LB-102 in patients with schizophrenia - marketscreener.com
LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia - The Manila Times
LB Pharmaceuticals Inc Initiates Pivotal Phase 3 Trial for LB -102 in Patients with Schizophrenia - MarketScreener
LB Pharmaceuticals Inc(NasdaqGM: LBRX) added to S&P Global BMI Index - MarketScreener
LB Pharmaceuticals Inc(NasdaqGM:LBRX) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
LB Pharmaceuticals CEO Maps LB-102 Milestones, Says Pipeline Fully Funded Into Q2 2029 - MarketBeat
LB Pharmaceuticals Inc: Fundamental Analysis and Financial Ratings | LBRX | US50180M1080 - marketscreener.com
LBRX: LB-102 advances toward pivotal data in major CNS indications, fully funded through 2029 - TradingView
LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Down 4.6%Should You Sell? - MarketBeat
LB Pharmaceuticals director Zachary Prensky to retire after 2026 annual meeting - Investing.com India
LB Pharmaceuticals director Zachary Prensky to retire after 2026 annual meeting By Investing.com - Investing.com South Africa
LB Pharmaceuticals Announces Director Zachary Prensky’s Planned Retirement - TipRanks
LB Pharmaceuticals (NASDAQ: LBRX) director to retire and serve as consultant - Stock Titan
Boxer Capital Management LLC Acquires Shares of 70,000 LB Pharmaceuticals Inc $LBRX - MarketBeat
Commodore Capital LP Invests $23.69 Million in LB Pharmaceuticals Inc $LBRX - MarketBeat
200,000 Shares in LB Pharmaceuticals Inc $LBRX Bought by Baker BROS. Advisors LP - MarketBeat
300,000 Shares in LB Pharmaceuticals Inc $LBRX Acquired by Nan Fung Group Holdings Ltd - MarketBeat
100,000 Shares in LB Pharmaceuticals Inc $LBRX Purchased by Integral Health Asset Management LLC - MarketBeat
LB Pharmaceuticals appoints Robert Lenz to board of directors By Investing.com - Investing.com Nigeria
LB Pharmaceuticals (NASDAQ:LBRX) Sets New 12-Month HighShould You Buy? - MarketBeat
Bipolar Depression Market Expected to Witness Accelerated Expansion During the Forecast Period (2026-2036) Amid Advancements in Psychiatric Therapies | DelveInsight - The Malaysian Reserve
LB Pharmaceuticals (LBRX) director receives 20,000 stock options vesting 2027–2029 - Stock Titan
LB Pharmaceuticals (LBRX) director Robert Lenz files initial Form 3 - Stock Titan
LB Pharmaceuticals adds neuroscience leader to board, governance - TipRanks
LB Pharmaceuticals (Nasdaq: LBRX) names new director and COO - Stock Titan
LB Pharmaceuticals Inc Approves the Promotion of Gad Soffer, the Chief Business Officer, to the Position of Chief Operating and Business Officer, Effective March 4, 2026 - marketscreener.com
Certain Stock Options of LB Pharmaceuticals Inc are subject to a Lock-Up Agreement Ending on 10-MAR-2026. - marketscreener.com
3,433,470 Common Stock of LB Pharmaceuticals Inc are subject to a Lock-Up Agreement Ending on 10-MAR-2026. - marketscreener.com
LB Pharmaceuticals appoints Robert Lenz to board of directors - Investing.com
LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors - Bitget
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):